Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710734 · ClinicalTrials.gov registry record · Phase 2
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
A Phase 2 study of Urothelial Carcinoma of the Bladder, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 4
- Study locations
NCT02710734: Active Phase 2 study of Urothelial Carcinoma of the Bladder, sponsored by Fox Chase Cancer Center.
NCT02710734 is a Phase 2 study of Urothelial Carcinoma of the Bladder that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02710734, a Phase 2 study of Urothelial Carcinoma of the Bladder, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) chemotherapy. Based on the mutational profile and the post AMVAC TURBT findings, patients will be treated with active surveillance (experimental arm), or standard of care intravesicle therapy, chemoradiation or surgery. We hypothesize that this approach will lead to non-inferior metastasis-free survival at 2 years, while preserving the bladder and thus quality-of-life for a proportion of patients.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Methotrexate
- RADIATION Intensity modulated radiation therapy (IMRT)
- DRUG Vinblastine
Study Locations (4)
Pennsylvania
- Sidney kimmel Cancer Center - Philadelphia
- Fox Chase Cancer Center - Philadelphia
District of Columbia
- Washington Cancer Institute at MedStar Washington Hospital Center - Washington D.C.
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2016-02-24 |
| Est. Completion | 2034-02 |
| Phase | Phase 2 |
What the registry record for NCT02710734 still lists
NCT02710734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Urothelial Carcinoma of the Bladder appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT02710734 reports a single indexed study location in Pennsylvania, District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT02710734 about?
NCT02710734 is a clinical study titled "Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)". The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplati...
What is the current status of trial NCT02710734?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2016-02-24. Estimated completion is 2034-02.
What conditions does trial NCT02710734 study?
This clinical trial studies the following conditions: Urothelial Carcinoma of the Bladder.
What interventions are being tested in trial NCT02710734?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Methotrexate (DRUG), Intensity modulated radiation therapy (IMRT) (RADIATION), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT02710734?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710734 being conducted?
This trial has 4 study locations across District of Columbia, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma of the Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02710734's enrollment target sits among peer trials
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI